Newsfeed

Bei diesem Bereich handelt es sich um eine mögliche Darstellungsform der Integration von Nachrichtenquellen mit Bezug zu börsennotierten Unternehmen.
Als Präsentationsebene fungiert ein Template, dass an Kurznachrichtenservices angelehnt ist, bei dem sich Nutzer einen schnellen Überblick über aktuelle Nachrichten verschaffen können. Die Detailansichten ermöglichen bei Interesse weitergehende Recherchen.

Dieser Newsfeed ist eine Zusammenstellung aktueller Nachrichten, die aus Direktanbindungen von TopTier NewsWire-Services mit Bezug zu börsennotierten Unternehmen stammen. Dieser Feed hier dient ausschließlich Demonstrationszwecken. Sektoren-spezifische Nachrichten, Public Relations sowie Produktinformationen können über die GICS Portale > Bereich Sektor-Intelligence abgerufen werden.

US7170811035
Filter zurücksetzen
Do you already know our new terminal view? Click here.
FIGI: BBG000BR2B91
PFE
Pfizer Inc
GICS: Health Care · SECTOR: EQTY · SUB-SECTOR: Drug Manufacturers - General · THEMEFOLIO: $TF-77
NAME
Pfizer Inc
ISIN
US7170811035
TICKER
PFE
MIC
XNYS
REUTERS
PFE.N
BLOOMBERG
PFE US
Do., 09.04.2026       Pfizer
US7170811035

Pfizer Inc. (NYSE: PFE) announced today that its shareholders and the general public are invited to access its virtual 2026 Annual Meeting of Shareholders on Thursday, April 23, 2026, at 9:00 a.m. EDT. Shareholders can find information on accessing and registering for the virtual meeting at https://meetnow.global/PFE2026. On the day of the Annua...
Zur Nachricht
Pfizer
Charts & Research Termsheets Terminal
Permalink
Di., 24.03.2026       Pfizer
US7170811035

Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 10:00 a.m. EDT on Tuesday, May 5, 2026. The purpose of the call is to provide an update on Pfizer’s results, as reflected in the company’s First Quarter 2026 Performance Report, to be issued that morning...
Zur Nachricht
Pfizer
Charts & Research Termsheets Terminal
Permalink
Mo., 23.03.2026       Pfizer
US7170811035

Pfizer Inc. (NYSE: PFE) and Valneva SE (Nasdaq: VALN; Euronext Paris: VLA) today announced topline results from the Phase 3 VALOR “Vaccine Against Lyme for Outdoor Recreationists” clinical trial (NCT05477524) of its investigational 6-valent OspA-based Lyme disease vaccine candidate PF-07307405 (LB6V, formerly known as VLA15) demonstrating: In t...
Zur Nachricht
Pfizer
Charts & Research Termsheets Terminal
Permalink
Fr., 20.03.2026       Pfizer
US7170811035

Pfizer Inc. (NYSE: PFE) today announced that it has received notice of an unsolicited mini-tender offer by Tutanota LLC (“Tutanota”) to purchase up to 1 million shares of Pfizer common stock at a price of $32.00 per share in cash. The offer price of $32.00 per share is conditioned on, among other things, the closing price per share of Pfizer commo...
Zur Nachricht
Pfizer
Charts & Research Termsheets Terminal
Permalink
Do., 19.03.2026       Pfizer
US7170811035

Pfizer Inc. (NYSE: PFE) today announced positive topline results from the Phase 3 TALAPRO-3 study of TALZENNA® (talazoparib), an oral poly ADP-ribose polymerase (PARP) inhibitor, in combination with XTANDI® (enzalutamide), an androgen receptor pathway inhibitor (ARPI), in people with homologous recombination repair (HRR) gene-mutated metastatic ca...
Zur Nachricht
Pfizer
Charts & Research Termsheets Terminal
Permalink
Di., 17.03.2026       Pfizer
US7170811035

Pfizer Inc. (NYSE: PFE) today announced positive topline results from the randomized Phase 2 FOURLIGHT-1 study evaluating atirmociclib in combination with fulvestrant, versus fulvestrant or everolimus plus exemestane, in people with hormone receptor (HR)-positive, human epidermal growth factor receptor 2-negative (HER2-) advanced or metastatic bre...
Zur Nachricht
Pfizer
Charts & Research Termsheets Terminal
Permalink
Mo., 09.03.2026       Pfizer
US7170811035

Pfizer Inc. (NYSE: PFE) today announced positive topline results from a Phase 2 study investigating tilrekimig (PF-07275315) in adults with moderate to severe atopic dermatitis. The study met its primary efficacy endpoint, demonstrating a statistically significant increase in the percentage of participants achieving EASI-75* (≥ 75% reduction in th...
Zur Nachricht
Pfizer
Charts & Research Termsheets Terminal
Permalink
Fr., 27.02.2026       Pfizer
US7170811035

Pfizer Inc. (NYSE: PFE) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, “Astellas”) today announced positive results from the Phase 3 EV-304 clinical trial (also known as KEYNOTE-B15) for PADCEVTM (enfortumab vedotin), a Nectin-4 directed antibody-drug conjugate, in combination with Keytruda® (pembrolizumab), a PD-1 inhibito...
Zur Nachricht
Pfizer
Charts & Research Termsheets Terminal
Permalink
Di., 24.02.2026       Pfizer
US7170811035

Pfizer Inc. (NYSE: PFE) today announced that the U.S. Food and Drug Administration (FDA) has granted full approval to BRAFTOVI® (encorafenib) in combination with cetuximab (marketed as ERBITUX®) and fluorouracil-based chemotherapy for the treatment of adult patients with metastatic colorectal cancer (mCRC) with a BRAF V600E mutation based on resul...
Zur Nachricht
Pfizer
Charts & Research Termsheets Terminal
Permalink
Mo., 23.02.2026       Pfizer
US7170811035

Pfizer Inc. (NYSE: PFE) invites investors and the general public to listen to a webcast of a discussion with Albert Bourla, Chairman and Chief Executive Officer, at the TD Cowen 46th Annual Health Care Conference on Monday, March 2, 2026 at 10:30 a.m. EST. To listen to the webcast, visit our web site at www.pfizer.com/investors. Information on a...
Zur Nachricht
Pfizer
Charts & Research Termsheets Terminal
Permalink
Silent Ad
Di., 17.02.2026       Pfizer
US7170811035

Pfizer Inc. (NYSE: PFE) today announced positive topline progression-free (PFS) survival results from Cohort 3, a separate randomized cohort of the pivotal BREAKWATER trial, evaluating BRAFTOVI® (encorafenib) in combination with cetuximab (marketed as ERBITUX®) and FOLFIRI (fluorouracil, leucovorin, and irinotecan) in patients with previously untr...
Zur Nachricht
Pfizer
Charts & Research Termsheets Terminal
Permalink
Fr., 06.02.2026       Pfizer
US7170811035

Pfizer Inc. (NYSE: PFE) today announced that the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review for the company’s supplemental Biologics License Application (sBLA) for HYMPAVZI® (marstacimab) to expand the approved indication to include the treatment of hemophilia A or B patients 6 years and older with inhibitors,...
Zur Nachricht
Pfizer
Charts & Research Termsheets Terminal
Permalink
Fr., 06.02.2026       Pfizer
US7170811035

Pfizer Inc. (NYSE: PFE) today announced the launch of its program on TrumpRx, making innovative medicines more affordable and accessible to millions of Americans. Starting today, the program provides Americans a wide range of more than 30 medicines at a significant discount off list prices. This effort is part of Pfizer’s broader landmark Most Fav...
Zur Nachricht
Pfizer
Charts & Research Termsheets Terminal
Permalink
Di., 03.02.2026       Pfizer
US7170811035

Pfizer Inc. (NYSE: PFE) reported financial results for fourth-quarter and full-year 2025 and reaffirmed its full-year 2026 financial guidance(1) provided on December 16, 2025. EXECUTIVE COMMENTARY Dr. Albert Bourla, Chairman and CEO of Pfizer: “With excellent execution in 2025, we delivered a solid financial performance and strengthened Pfiz...
Zur Nachricht
Pfizer
Charts & Research Termsheets Terminal
Permalink
Di., 03.02.2026       Pfizer
US7170811035

Pfizer Inc. (NYSE: PFE) today announced positive topline results from the Phase 2b VESPER-3 study investigating monthly maintenance dosing of its fully-biased, ultra-long-acting, injectable GLP-1 receptor agonist (RA) PF’3944 (MET-097i) in adults with obesity or overweight without type 2 diabetes. The study had two objectives: (1) to demonstrate...
Zur Nachricht
Pfizer
Charts & Research Termsheets Terminal
Permalink
Do., 22.01.2026       Pfizer
US7170811035

Das Instrument PFE US7170811035 PFIZER INC. DL-,05 EQUITY wird ex Dividende/Zinsen gehandelt am 23.01.2026 The instrument PFE US7170811035 PFIZER INC. DL-,05 EQUITY has its ex-dividend/interest day on 23.01.2026...
Zur Nachricht
Pfizer
Charts & Research Termsheets Terminal
Permalink
Do., 22.01.2026       Pfizer
US7170811035

Das Instrument PFE US7170811035 PFIZER INC. DL-,05 EQUITY wird ex Dividende/Zinsen gehandelt am 23.01.2026 The instrument PFE US7170811035 PFIZER INC. DL-,05 EQUITY has its ex-dividend/interest day on 23.01.2026...
Zur Nachricht
Pfizer
Charts & Research Termsheets Terminal
Permalink
Mi., 21.01.2026       Pfizer
US7170811035

Das Instrument PFE US7170811035 PFIZER INC. DL-,05 EQUITY wird cum Dividende/Zinsen gehandelt am 22.01.2026 und ex Dividende/Zinsen am 23.01.2026 The instrument PFE US7170811035 PFIZER INC. DL-,05 EQUITY has its pre-dividend/interest day on 22.01.2026 and its ex-dividend/interest day on 23.01.2026...
Zur Nachricht
Pfizer
Charts & Research Termsheets Terminal
Permalink
Mi., 21.01.2026       Pfizer
US7170811035

Das Instrument PFE US7170811035 PFIZER INC. DL-,05 EQUITY wird cum Dividende/Zinsen gehandelt am 22.01.2026 und ex Dividende/Zinsen am 23.01.2026 The instrument PFE US7170811035 PFIZER INC. DL-,05 EQUITY has its pre-dividend/interest day on 22.01.2026 and its ex-dividend/interest day on 23.01.2026...
Zur Nachricht
Pfizer
Charts & Research Termsheets Terminal
Permalink
Sa., 10.01.2026       Pfizer
US7170811035

Pfizer Inc. (NYSE: PFE) today announced positive results from Cohort 3, a separate randomized cohort of the pivotal BREAKWATER trial, evaluating BRAFTOVI® (encorafenib) in combination with cetuximab (marketed as ERBITUX®) and FOLFIRI (fluorouracil, leucovorin, and irinotecan) in patients with previously untreated metastatic colorectal cancer (mCRC...
Zur Nachricht
Pfizer
Charts & Research Termsheets Terminal
Permalink
Silent Ad
Mi., 07.01.2026       Pfizer
US7170811035

At a Case Management Conference in the Multi District Litigation against Pfizer Inc. (NYSE:PFE), the Honorable M. Casey Rodgers set a date for the first Trial, which will take place in December 2026, as more than 2,100 women pursue litigation alleging Pfizer failed to adequately warn patients despite long-standing knowledge of the risk. The hear...
Zur Nachricht
Pfizer
Charts & Research Termsheets Terminal
Permalink
Mo., 05.01.2026       Pfizer
US7170811035

Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a discussion with Albert Bourla, Chairman and Chief Executive Officer, at the 44th Annual J.P. Morgan Healthcare Conference on Monday, January 12, 2026 at 9:45 a.m. PST. To view and listen to the webcast, visit our web site at www.pfizer.com/inves...
Zur Nachricht
Pfizer
Charts & Research Termsheets Terminal
Permalink
Do., 18.12.2025       Pfizer
US7170811035

Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 10:00 a.m. EST on Tuesday, February 3, 2026. The purpose of the call is to provide an update on Pfizer’s results, as reflected in the company’s Fourth Quarter and Full Year 2025 Performance Report, to be...
Zur Nachricht
Pfizer
Charts & Research Termsheets Terminal
Permalink
Mi., 17.12.2025       Pfizer
US7170811035

PADCEV plus Keytruda is the first and only regimen without platinum-based chemotherapy to improve event-free and overall survival when used before and after surgery in cisplatin-eligible patients with muscle-invasive bladder cancer Positive EV-304 data, combined with the recent unprecedented results from the EV-303 trial, highlight the potential o...
Zur Nachricht
Pfizer
Charts & Research Termsheets Terminal
Permalink
Di., 16.12.2025       Pfizer
US7170811035

Pfizer Inc. (NYSE:PFE) today provided its full-year 2026 guidance(2) while revising its November 4, 2025 full-year 2025 Revenue guidance(2) and reaffirming all other components of full-year 2025 financial guidance(2). The accompanying presentation can be found at www.pfizer.com/investors. FULL-YEAR 2026 REVENUE GUIDANCE(2) Pfizer anticipates ful...
Zur Nachricht
Pfizer
Charts & Research Termsheets Terminal
Permalink
Fr., 12.12.2025       Pfizer
US7170811035

Pfizer Inc. (NYSE: PFE) today announced that its board of directors declared a $0.43 first-quarter 2026 dividend on the company’s common stock, payable March 6, 2026, to holders of the Common Stock of record at the close of business on January 23, 2026. The first-quarter 2026 cash dividend will be the 349th consecutive quarterly dividend paid by P...
Zur Nachricht
Pfizer
Charts & Research Termsheets Terminal
Permalink
Mi., 10.12.2025       Pfizer
US7170811035

Pfizer Inc. (NYSE: PFE) today announced detailed results from the Phase 3 HER2CLIMB-05 trial of the tyrosine kinase inhibitor TUKYSA® (tucatinib) as part of an investigational first-line maintenance treatment combination, following chemotherapy-based induction, in patients with human epidermal growth factor receptor 2-positive (HER2+) metastatic b...
Zur Nachricht
Pfizer
Charts & Research Termsheets Terminal
Permalink
Di., 09.12.2025       Pfizer
US7170811035

Pfizer Inc. (NYSE: PFE) today announced it has entered into an exclusive global collaboration and license agreement with YaoPharma, a subsidiary of Shanghai Fosun Pharmaceutical (Group) Co., Limited (02196.HK and 600106.SH), a leading innovation-driven global healthcare company, for the development, manufacturing and commercialization of YP05002,...
Zur Nachricht
Pfizer
Charts & Research Termsheets Terminal
Permalink
Sa., 06.12.2025       Pfizer
US7170811035

Pfizer Inc. (NYSE: PFE) today presented results from the Phase 3 BASIS study (NCT03938792) evaluating HYMPAVZI® (marstacimab) for adults and adolescents living with hemophilia A or B with inhibitors. The results demonstrated the superiority of HYMPAVZI in improving key bleeding outcomes compared to on-demand (OD) treatment with bypassing agents. H...
Zur Nachricht
Pfizer
Charts & Research Termsheets Terminal
Permalink
Mo., 01.12.2025       Pfizer
US7170811035

Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 8:00 a.m. EST on Tuesday, December 16, 2025. The purpose of the call is to provide Pfizer’s full-year 2026 financial guidance. To view and listen to the webcast, visit our web site at www.pfizer.com/inv...
Zur Nachricht
Pfizer
Charts & Research Termsheets Terminal
Permalink
Fr., 21.11.2025       Pfizer
US7170811035

Pfizer Inc. (NYSE: PFE) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, “Astellas”) today announced that the U.S. Food and Drug Administration (FDA) has approved PADCEV® (enfortumab vedotin-ejfv), a Nectin-4 directed antibody-drug conjugate (ADC), in combination with the PD-1 inhibitor Keytruda® (pembrolizumab) or Keytruda Q...
Zur Nachricht
Pfizer
Charts & Research Termsheets Terminal
Permalink
Do., 13.11.2025       Pfizer
US7170811035

Pfizer Inc. (NYSE: PFE) today announced the successful completion of its acquisition of Metsera, Inc. (NASDAQ: MTSR), a clinical-stage biopharmaceutical company accelerating the next generation of medicines for obesity and cardiometabolic diseases. “This strategic milestone represents more than a transaction—it's a deliberate investment in the f...
Zur Nachricht
Pfizer
Charts & Research Termsheets Terminal
Permalink
Mi., 12.11.2025       Pfizer
US7170811035

Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a discussion with Dave Denton, Chief Financial Officer, Executive Vice President, at the Jefferies London Healthcare Conference on Wednesday, November 19, 2025 at 9:00 a.m. GMT. To view and listen to the webcast, visit our web site at www.pfizer.c...
Zur Nachricht
Pfizer
Charts & Research Termsheets Terminal
Permalink
Do., 06.11.2025       Pfizer
US7170811035

Das Instrument PFE US7170811035 PFIZER INC. DL-,05 EQUITY wird ex Dividende/Zinsen gehandelt am 07.11.2025 The instrument PFE US7170811035 PFIZER INC. DL-,05 EQUITY has its ex-dividend/interest day on 07.11.2025...
Zur Nachricht
Pfizer
Charts & Research Termsheets Terminal
Permalink
Mi., 05.11.2025       Pfizer
US7170811035

Pfizer Inc. (NYSE: PFE) today issued the following statement in response to the Delaware Chancery Court’s decision denying Pfizer’s request for a temporary restraining order to prevent Metsera, Inc. from terminating the existing merger agreement in favor of a competing proposal from Novo Nordisk. “We remain confident in the merits of our claims a...
Zur Nachricht
Pfizer
Charts & Research Termsheets Terminal
Permalink
Mi., 05.11.2025       Pfizer
US7170811035

Das Instrument PFE US7170811035 PFIZER INC. DL-,05 EQUITY wird cum Dividende/Zinsen gehandelt am 06.11.2025 und ex Dividende/Zinsen am 07.11.2025 The instrument PFE US7170811035 PFIZER INC. DL-,05 EQUITY has its pre-dividend/interest day on 06.11.2025 and its ex-dividend/interest day on 07.11.2025...
Zur Nachricht
Pfizer
Charts & Research Termsheets Terminal
Permalink
Di., 04.11.2025       Pfizer
US7170811035

Pfizer Inc. (NYSE: PFE) reported financial results for the third quarter of 2025 and reaffirmed its 2025 Revenue guidance(1) while raising and narrowing guidance for Adjusted(2) diluted EPS. EXECUTIVE COMMENTARY Dr. Albert Bourla, Chairman and CEO of Pfizer: “I am proud of Pfizer’s leadership as the first in our industry to reach an agreemen...
Zur Nachricht
Pfizer
Charts & Research Termsheets Terminal
Permalink
Mo., 03.11.2025       Pfizer
US7170811035

Pfizer Inc. today announced that it has filed a second lawsuit against Metsera, Inc., its controlling stockholders, and Novo Nordisk A/S in the United States District Court for the District of Delaware. The lawsuit asserts that Novo Nordisk’s recent proposal to acquire Metsera constitutes an anticompetitive action by Novo Nordisk to protect its...
Zur Nachricht
Pfizer
Charts & Research Termsheets Terminal
Permalink
Fr., 31.10.2025       Pfizer
US7170811035

Pfizer Inc. today announced that it has filed a lawsuit against Metsera, Inc., its Board of Directors, and Novo Nordisk, S.A. in the Delaware Court of Chancery. The lawsuit asserts claims for breach of contract, breach of fiduciary duty, and tortious interference in contract arising from Metsera’s breach of its obligations under the merger agreeme...
Zur Nachricht
Pfizer
Charts & Research Termsheets Terminal
Permalink
Fr., 31.10.2025       Pfizer
US7170811035

Pfizer Inc. (NYSE: PFE) today announced the U.S. Federal Trade Commission has granted early termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (the “HSR Act”), with respect to Pfizer’s pending acquisition of Metsera (NASDAQ: MTSR). The termination of the waiting period under the HSR Act s...
Zur Nachricht
Pfizer
Charts & Research Termsheets Terminal
Permalink
Do., 30.10.2025       Pfizer
US7170811035

Pfizer Inc. (NYSE: PFE) is aware of the reckless and unprecedented proposal by Novo Nordisk A/S (NYSE: NVO) to acquire Metsera, Inc. (NASDAQ: MTSR). It is an attempt by a company with a dominant market position to suppress competition in violation of law by taking over an emerging American challenger. It is also structured in a way to circumvent a...
Zur Nachricht
Pfizer
Charts & Research Termsheets Terminal
Permalink
So., 19.10.2025       Pfizer
US7170811035

Pfizer Inc. (NYSE: PFE) and Astellas Pharma U.S. Inc. (Head of Commercial: Mike Petroutsas, "Astellas") today announced final overall survival (OS) results from the Phase 3 EMBARK study evaluating XTANDI® (enzalutamide), in combination with leuprolide and as monotherapy, in men with non-metastatic hormone-sensitive prostate cancer (nmHSPC; also kn...
Zur Nachricht
Pfizer
Charts & Research Termsheets Terminal
Permalink
So., 19.10.2025       Pfizer
US7170811035

Pfizer Inc. (NYSE: PFE) today announced updated follow-up results from the single-arm Phase 2 PHAROS trial evaluating BRAFTOVI® (encorafenib) + MEKTOVI® (binimetinib) for the treatment of adults with metastatic non-small cell lung cancer (mNSCLC) with a BRAF V600E mutation. In treatment-naïve patients, the median overall survival (OS) was 47.6 mon...
Zur Nachricht
Pfizer
Charts & Research Termsheets Terminal
Permalink
Sa., 18.10.2025       Pfizer
US7170811035

First and only combination regimen to improve survival when used before and after surgical cystectomy in cisplatin-ineligible patients with muscle-invasive bladder cancer Unprecedented survival results from pivotal Phase 3 EV-303 trial...
Zur Nachricht
Pfizer
Charts & Research Termsheets Terminal
Permalink
Di., 14.10.2025       Pfizer
US7170811035

Pfizer Inc. (NYSE: PFE) today announced positive topline results from the Phase 3 HER2CLIMB-05 trial of first-line combination therapy with the tyrosine kinase inhibitor TUKYSA® (tucatinib) in patients with human epidermal growth factor receptor 2-positive (HER2+) metastatic breast cancer (MBC). HER2CLIMB-05 is evaluating TUKYSA versus placebo, bo...
Zur Nachricht
Pfizer
Charts & Research Termsheets Terminal
Permalink
Mo., 13.10.2025       Pfizer
US7170811035

Pfizer Inc. (NYSE: PFE, “Pfizer”) will present data across its infectious disease portfolio at the upcoming IDWeek 2025 congress, held in Atlanta from October 19-22, 2025. Data in 46 abstracts from company- and collaborator-led studies will showcase significant advancements in preventing and treating infectious diseases. “IDWeek 2025 offers a cr...
Zur Nachricht
Pfizer
Charts & Research Termsheets Terminal
Permalink
Do., 09.10.2025       Pfizer
US7170811035

Pfizer Inc. (NYSE: PFE) today announced that its board of directors declared a $0.43 fourth-quarter 2025 dividend on the company’s common stock, payable December 1, 2025, to holders of the Common Stock of record at the close of business on November 7, 2025. The fourth-quarter 2025 cash dividend will be the 348th consecutive quarterly dividend paid...
Zur Nachricht
Pfizer
Charts & Research Termsheets Terminal
Permalink
Di., 30.09.2025       Pfizer
US7170811035

Pfizer Inc. (NYSE: PFE) today announced a historic agreement with the Trump Administration that will ensure U.S. patients pay lower prices for their prescription medicines while strengthening America’s role as the global leader in biopharmaceutical innovation. In response to the four points covered in the President’s July 31st letter, Pfizer has...
Zur Nachricht
Pfizer
Charts & Research Termsheets Terminal
Permalink
Do., 25.09.2025       Pfizer
US7170811035

A hearing in the Depo-Provera legal action against Pfizer Inc. (NYSE:PFE) will take place on Monday, 29 September at 9:00am CT in the United States Courthouse in Pensacola, Florida. The hearing will address oral arguments from the plaintiffs and defendants concerning the issue of pre-emption. The pre-emption defence is common in drug litigation. I...
Zur Nachricht
Pfizer
Charts & Research Termsheets Terminal
Permalink
Do., 25.09.2025       Pfizer
US7170811035

Pfizer Inc. (NYSE: PFE) will highlight data across its extensive Oncology portfolio at the European Society for Medical Oncology (ESMO) Congress 2025, being held October 17-21 in Berlin, Germany. Data from more than 45 company-sponsored, investigator-sponsored, and collaborative research abstracts, including 11 oral/mini oral presentations and fiv...
Zur Nachricht
Pfizer
Charts & Research Termsheets Terminal
Permalink